newsfilter
← Latest News
GlobeNewswire·

Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson's Disease

Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson's disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Nov.